Topical NSAIDs are meaningfully safer than oral NSAIDs for most people, particularly when it comes to stomach and heart risks. The key reason is simple: when you rub an NSAID gel or patch onto your skin, only a small fraction of the drug reaches your bloodstream. For diclofenac, the most studied topical NSAID, systemic absorption is roughly 6 to 7% of what you’d get from swallowing a pill. That dramatic difference in blood levels translates directly into fewer serious side effects.
The safety advantage does come with a tradeoff. Topical NSAIDs work best for superficial joints like knees and hands, and they cause local skin reactions that oral versions don’t. Here’s what the evidence actually shows across every major risk category.
How Much Drug Actually Enters Your Body
The pharmacokinetics tell a clear story. According to FDA review data for topical diclofenac gel, even at the maximum recommended use (12 grams applied four times daily), peak blood levels reach only about 2% of what a single 50-milligram oral tablet produces. Total drug exposure over 24 hours is roughly 20% of the oral dose. The relative bioavailability, which accounts for the different amounts of drug applied versus swallowed, sits at approximately 6.5%.
This matters because nearly every serious NSAID side effect is driven by the drug circulating through your bloodstream and affecting organs far from the painful joint. When 93% of the drug stays out of your system, the risks to your stomach lining, kidneys, and blood vessels drop substantially.
Stomach and Digestive Risks
Gastrointestinal problems are the most common serious concern with oral NSAIDs. About 15% of people taking oral NSAIDs experience digestive side effects ranging from heartburn and nausea to ulcers and bleeding. With topical NSAIDs, GI complications are described as “very rare” in the medical literature. Reported GI bleeding from topical NSAID patches is so uncommon that, as of recent reviews, only five such cases had been documented in Japan’s medical literature.
A large case-control study from Scotland involving over 1,100 patients found no significant independent association between topical NSAID use and upper gastrointestinal bleeding or perforation. The adjusted odds ratio was 1.06, meaning essentially no increased risk compared to non-users. That’s a stark contrast with oral NSAIDs, which roughly double to quadruple the risk of serious GI events depending on the specific drug and dose.
Heart Attack and Stroke Risk
Oral NSAIDs are well established to increase cardiovascular risk, including heart attacks and strokes. The picture for topical NSAIDs is more reassuring, though less extensively studied over long periods.
A study of Taiwanese patients with rheumatoid arthritis compared cardiovascular event rates between topical and oral NSAID users. The crude event rate was 1.87 per 100 person-years for topical users versus 2.14 for oral users. After adjusting for differences between the groups, topical NSAID users had a 36% lower risk of cardiovascular events (heart attacks, strokes, heart failure, or unstable angina) compared to oral users. That protective gap held up even among patients who already had cardiovascular disease.
One important caveat: most clinical trials of topical NSAIDs last 12 weeks or less, which isn’t long enough to fully evaluate long-term cardiovascular or kidney safety. The reduced blood levels strongly suggest lower risk, but the long-term data isn’t as robust as it is for GI safety.
The FDA Still Requires the Same Warning Label
Despite the evidence of lower systemic risk, the FDA requires prescription topical NSAIDs to carry the same boxed warning as oral versions. This warning states that NSAIDs increase the risk of serious cardiovascular events and gastrointestinal bleeding, ulceration, and perforation. The agency applies this class-wide warning to all prescription NSAIDs regardless of delivery method.
This is worth knowing because it can create confusion. The warning label on your topical NSAID looks identical to the one on an oral pill, but the actual risk profile is not identical. The FDA also specifically warns against combining topical and oral NSAIDs, noting that using both together can increase bleeding risk and lead to abnormal kidney function markers.
Skin Irritation: The Topical Tradeoff
Where topical NSAIDs do cause more problems than oral versions is at the application site. Roughly 10 to 15% of topical NSAID users experience local side effects, and 95% of all adverse events from topical NSAIDs are skin reactions: redness, itching, rash, or dryness at the spot where the gel or patch is applied. For diclofenac gel specifically, application site reactions affect about 6 to 9% of users depending on age.
Some topical NSAIDs also carry a risk of photosensitivity or contact photoallergy, where the treated skin becomes unusually reactive to sunlight. Ketoprofen is the worst offender here, responsible for 82% of contact photoallergies among topical NSAIDs in one large dermatology review, despite being only the third most commonly used topical NSAID. Diclofenac causes far fewer allergic skin reactions.
These skin reactions are annoying but not dangerous. For most people, they’re a worthwhile tradeoff compared to the stomach and cardiovascular risks of oral NSAIDs.
Pain Relief Is Comparable for Accessible Joints
A common assumption is that topical NSAIDs must sacrifice effectiveness for safety. For osteoarthritis of the knee, the evidence says otherwise. A systematic review and meta-analysis comparing topical and oral NSAIDs for osteoarthritis found no meaningful difference in pain relief or physical function. The differences in pain scores on standard scales were statistically negligible.
This equivalence is why current treatment guidelines from the American College of Rheumatology list both topical and oral NSAIDs as strongly recommended options for knee osteoarthritis. For hand osteoarthritis, topical NSAIDs receive a conditional recommendation, reflecting slightly less certainty about their effectiveness in smaller joints.
The limitation is anatomical. Topical NSAIDs work by penetrating through the skin into the tissue directly beneath. Joints that sit close to the surface, like the knee and finger joints, get adequate local drug concentrations. Deeper structures like the hip or spine don’t benefit as much from topical application because the drug can’t penetrate deeply enough in therapeutic amounts. For pain in those areas, oral NSAIDs or other approaches are generally more effective.
Safety in Older Adults
Adults over 65 are the group most vulnerable to oral NSAID side effects. They’re at higher risk for GI bleeding, more likely to have heart disease or reduced kidney function, and more often taking blood thinners that interact with NSAIDs. This makes the topical-versus-oral question especially important for older adults.
Pooled data from three 12-week trials of topical diclofenac gel for knee osteoarthritis found that GI side effect rates were similar between patients under 65 and those 65 and older (ranging from 4.0 to 5.1% across all groups). Application site reactions were slightly more common in older adults (8.8% versus 5.6%), but overall tolerability was comparable across age groups.
One area of caution: there’s some signal from unpublished data suggesting that older adults using topical NSAIDs may have a slightly higher risk of GI events than younger users, though this finding did not reach statistical significance. People taking blood thinners like warfarin should also be aware that certain topical formulations, particularly those containing methyl salicylate, can amplify the anticoagulant effect and increase bleeding risk. Five such cases were documented in one review, with one resulting in GI bleeding.
For the majority of older adults managing knee or hand arthritis, topical NSAIDs offer a way to get comparable pain relief while largely sidestepping the systemic risks that make oral NSAIDs so problematic in this age group.